HAYWARD, Calif., Nov. 7, 2000 (PRIMEZONE) -- Questcor Pharmaceuticals, Inc. (AMEX:QSC), a fully integrated specialty pharmaceutical company focusing on serving the acute care and critical care hospital markets, announced today that its CEO, Charles J. Casamento, will appear at the Equities Magazine Conference in New York City to review the Company's recent accomplishments and future growth plans to analysts, money managers, investment bankers and investors.
The Fall Conference III, sponsored by the Equities Magazine, is being held on Thursday, November 9th at the Grand Hyatt Hotel, on 42nd Street at Grand Central Terminal in New York City. Mr. Charles J. Casamento, Questcor's CEO, will be making a formal presentation at 9:00 AM. He will also be available for private meetings with analysts, portfolio managers, media and other members of the investment community later that day, and will make brief remarks at the "Parade of Presidents" Luncheon at 12:00 noon.
"The Equities Magazine Corporate Conference is an excellent venue to report Questcor's progress and achievements to hundreds of Wall Street professionals and institutional investors, including our shareholders in New York City. These activities further improve our Company's visibility and market presence," said Mr. Casamento.
Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company whose focus is to serve the needs of the acute care and critical care hospital market. The Company's strategy includes the acquisition and marketing of hospital pharmaceutical products, the generation of revenue streams from these products and the continued funding of late stage, acute care and critical care pharmaceutical research and development programs. As part of a strategy to develop its products globally, Questcor has entered into contractual relationships with CSC Pharmaceuticals HandelsGmbH of Vienna, Austria; Crinos Group of Como, Italy; Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan; NutraMax Products, Inc. of Gloucester, MA; Rigel Pharmaceuticals, Inc. of South San Francisco, CA; Shire Pharmaceuticals Group plc of Andover, UK; and Laboratorios Silesia S.A. of Santiago, Chile. Questcor was created as a result of the merger, on November 17, 1999, of RiboGene, Inc. and Cypros Pharmaceutical Corporation.
For more information on Questcor, please visit our website at www.questcor.com.
If you are interested in attending, please RSVP to Equities Magazine at (212) 213-1300, or register online at www.equitiesmagazine.com, or by contacting Richard Goldman of Alan Stone & Company LLC at (310) 444-3940, or via email at rgoldman@alanstone.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause the Company's results to differ. Factors that may cause such differences include, but are not limited to, the Company's need for additional funding, uncertainties regarding the company's intellectual property and other research, development, marketing and regulatory risks, and, the ability of the Company to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's transition report on Form 10-K for the fiscal year ended December 31, 1999, the Risk Factor section of Cypros' Registration Statement on form S-4 (No. 333-87611), and the Company's quarterly reports on form 10-Q ended March 31, 2000 and June 30, 2000 respectively, and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.